Tagrisso with the addition of chemo recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer June 11, 2024
IND Filing for PFL-002/VERT-002 for Patients with Solid Tumors Including NSCLC with MET Alterations June 11, 2024
FDA grants Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR WT NSCLC June 4, 2024
FAILED TRIAL: Datopotamab deruxtecan showed clinically meaningful OS improvement vs. chemo in patients with advanced nonsquamous NSCLC in TROPION-Lung01 Ph 3 trial May 29, 2024
NMPA of China Accepted and Granted Priority Review Designation to the NDA for Glecirasib May 29, 2024
US FDA accepts Protocol for New Randomized Ph 2 Study of NBTXR3 for Patients with Stage 3 Lung Cancer May 21, 2024
FDA approves Imdelltra™ (tarlatamab-dlle) for The Treatment Of Extensive-Stage Small Cell Lung Cancer May 21, 2024
U.S. FDA Accepts and grants Priority Review of BLA for Zeno for the Treatment of NRG1+ NSCLC and PDAC May 15, 2024
Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in interim assessment of Ph 2 GALAXIES Lung-201 May 15, 2024
FAILED TRIAL: Ph 3 CheckMate -73L trial did not meet primary endpoint of PFS in unresectable, locally advanced stage III NSCLC May 14, 2024
Positive OS Results of Anktiva Combined With Checkpoint Inhibitors in NSCLC Announced; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer May 1, 2024
Positive CHMP opinion for RYBREVANT (amivantamab) in combination with chemotherapy for the 1L treatment of patients with advanced NSCLC with activating EGFR exon 20 insertion mutations May 1, 2024
Move-Forward Ph 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous NSCLC selected April 23, 2024
FDA Approves Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer April 23, 2024
OSE Immunotherapeutics Receives €8.4 M in Public Funding for Registrational Ph 3 Trial of Cancer Vaccine Tedopi® in Lung Cancer April 16, 2024
Ph 3 Trial of MK-1084 + KEYTRUDA for 1L Treatment of Certain Patients With Metastatic NSCLC initiated April 9, 2024
Imfinzi significantly improved OS and PFS for patients with limited-stage SCLC in ADRIATIC Ph 3 trial April 8, 2024
